1. Chew MH, Yeh YT, Toh EL, Sumarli SA, Chew GK, Lee LS, et al. Critical evaluation of contemporary management in a new Pelvic Exenteration Unit: The first 25 consecutive cases. World J Gastrointest Oncol. 2017;9(5):218-27. [
DOI:10.4251/wjgo.v9.i5.218] [
PMID] [
PMCID]
2. Brar H, May T, Tau N, Langer D, MacCrostie P, Han K, et al. Detection of extra-regional tumour recurrence with 18F-FDG-PET/CT in patients with recurrent gynaecological malignancies being considered for radical salvage surgery. Clin Radiol. 2017;72(4):302-6. [
DOI:10.1016/j.crad.2016.12.009] [
PMID]
3. Guimarães GC, Baiocchi G, Ferreira FO, Kumagai LY, Fallopa CC, Aguiar S, et al. Palliative pelvic exenteration for patients with gynecological malignancies. Arch Gynecol Obstet. 2011;283(5):1107-12. [
DOI:10.1007/s00404-010-1544-8] [
PMID]
4. Gadducci A, Tana R, Cosio S, Cionini L. Treatment options in recurrent cervical cancer (Review). Oncol Lett. 2010;1(1):3-11. [
DOI:10.3892/ol_00000001] [
PMID] [
PMCID]
5. Berek JS, Howe C, Lagasse LD, Hacker NF. Pelvic exenteration for recurrent gynecologic malignancy: Survival and morbidity analysis of the 45-year experience at UCLA. Gynecol Oncol. 2005;99(1):153-9. [
DOI:10.1016/j.ygyno.2005.05.034] [
PMID]
6. Alameh T, Mousavi Seresht L, Afshar N, Mohamadi Jazi B. Is Uterine Cervix Lymphoma Missed Most of the Time? A Rare Case of Primary Cervical Lymphoma. J Obstet Gynecol Cancer Res. 2022;7(5):452-7. [
DOI:10.30699/jogcr.7.5.452]
7. Smith B, Jones EL, Kitano M, Gleisner AL, Lyell NJ, Cheng G, et al. Influence of tumor size on outcomes following pelvic exenteration. Gynecol Oncol. 2017;147(2):345-50. [
DOI:10.1016/j.ygyno.2017.08.014] [
PMID]
8. Uzan C, Rouzier R, Castaigne D, Pomel C. Laparoscopic pelvic exenteration for cervical cancer relapse: preliminary study. J Gynecol Obstet Biol Reprod 2006;35(2):136-45. [
DOI:10.1016/S0368-2315(06)76387-6] [
PMID]
9. Maharaj R, Sookdeo VD, Fortuné M, Akhilesh M, Venkata CRA, Mohammed W, et al. Pelvic exenteration case series: A single surgeon's experience at one institution in Trinidad and Tobago. Int J Surg Case Rep. 2017;34:4-10. [
DOI:10.1016/j.ijscr.2017.03.006] [
PMID] [
PMCID]
10. Schmidt AM, Imesch P, Fink D, Egger H. Indications and long-term clinical outcomes in 282 patients with pelvic exenteration for advanced or recurrent cervical cancer. Gynecol Oncol. 2012;125(3):604-9. [
DOI:10.1016/j.ygyno.2012.03.001] [
PMID]
11. Young JM, Badgery-Parker T, Masya LM, King M, Koh C, Lynch AC, et al. Quality of life and other patient-reported outcomes following exenteration for pelvic malignancy. Br J Surg. 2014;101(3):277-87. [
DOI:10.1002/bjs.9392] [
PMID]
12. Quyn AJ, Solomon MJ, Lee PM, Badgery-Parker T, Masya LM, Young JM. Palliative pelvic exenteration: clinical outcomes and quality of life. Dis Colon Rectum. 2016;59(11):1005-10. [
DOI:10.1097/DCR.0000000000000679] [
PMID]
13. Donati OF, Lakhman Y, Sala E, Burger IA, Vargas HA, Goldman DA, et al. Role of preoperative MR imaging in the evaluation of patients with persistent or recurrent gynaecological malignancies before pelvic exenteration. Eur Radiol. 2013;23(10):2906-15. [
DOI:10.1007/s00330-013-2875-1] [
PMID]
14. Brown WE, Koh CE, Badgery-Parker T, Solomon MJ. Validation of MRI and surgical decision making to predict a complete resection in pelvic exenteration for recurrent rectal cancer. Dis Colon Rectum. 2017;60(2):144-51. [
DOI:10.1097/DCR.0000000000000766] [
PMID]
15. Armbruster SD, Sun CC, Westin SN, Bodurka DC, Ramondetta L, Meyer LA, et al. Prospective assessment of patient-reported outcomes in gynecologic cancer patients before and after pelvic exenteration. Gynecol Oncol. 2018;149(3):484-90. [
DOI:10.1016/j.ygyno.2018.03.054] [
PMID] [
PMCID]
)